Loading…

Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia

Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from Janu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2007-03, Vol.59 (3), p.525-530
Main Authors: Kwon, Ki Tae, Oh, Won Sup, Song, Jae-Hoon, Chang, Hyun-Ha, Jung, Sook-In, Kim, Shin-Woo, Ryu, Seong Yeol, Heo, Sang Taek, Jung, Dong Sik, Rhee, Ji-Young, Shin, Sang Yop, Ko, Kwan Soo, Peck, Kyong Ran, Lee, Nam Yong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543
cites cdi_FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543
container_end_page 530
container_issue 3
container_start_page 525
container_title Journal of antimicrobial chemotherapy
container_volume 59
creator Kwon, Ki Tae
Oh, Won Sup
Song, Jae-Hoon
Chang, Hyun-Ha
Jung, Sook-In
Kim, Shin-Woo
Ryu, Seong Yeol
Heo, Sang Taek
Jung, Dong Sik
Rhee, Ji-Young
Shin, Sang Yop
Ko, Kwan Soo
Peck, Kyong Ran
Lee, Nam Yong
description Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. Results Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P < 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P < 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P < 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). Conclusions Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy.
doi_str_mv 10.1093/jac/dkl499
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70202552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkl499</oup_id><sourcerecordid>1317815101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543</originalsourceid><addsrcrecordid>eNqF0U1rFTEUBuAgFnutbvwBEgRdCNPmO5NlLdYWLnTTQnETMpkEczszGZMMtf_elLl4wYWuzubhTc55AXiH0SlGip7tjD3rHwam1AuwwUyghiCFX4INoog3knF6DF7nvEMICS7aV-AYS4IpEXwD7q7H2dgCo4dhDLOb3AiTyyEXM1kH4wTHmIoZQnmCYYKzKcFNJcPHUH7AcxsmV2JXA1yC6zBuDOYNOPJmyO7tfp6Au8uvtxdXzfbm2_XF-baxTMrSSEJaXn_SK-Mp4Uz2hmEllcNIKs-l99L3qvOyZ4ga1PasY6KzxFKPpeKMnoBPa-6c4s_F5aLHkK0bBjO5uGQtEUGEc_JfiBUXgklU4Ye_4C4uaapLaIKlaDESz2mfV2RTzDk5r-cURpOeNEb6uRJdK9FrJRW_3ycu3ej6A913UMHHPTDZmsGnevmQD64VRFDeHlxc5n8_2Kyuluh-_ZEmPWghqeT66v67vt9-UYJxpS_pbxS5r18</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217681062</pqid></control><display><type>article</type><title>Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia</title><source>Oxford Journals Online</source><creator>Kwon, Ki Tae ; Oh, Won Sup ; Song, Jae-Hoon ; Chang, Hyun-Ha ; Jung, Sook-In ; Kim, Shin-Woo ; Ryu, Seong Yeol ; Heo, Sang Taek ; Jung, Dong Sik ; Rhee, Ji-Young ; Shin, Sang Yop ; Ko, Kwan Soo ; Peck, Kyong Ran ; Lee, Nam Yong</creator><creatorcontrib>Kwon, Ki Tae ; Oh, Won Sup ; Song, Jae-Hoon ; Chang, Hyun-Ha ; Jung, Sook-In ; Kim, Shin-Woo ; Ryu, Seong Yeol ; Heo, Sang Taek ; Jung, Dong Sik ; Rhee, Ji-Young ; Shin, Sang Yop ; Ko, Kwan Soo ; Peck, Kyong Ran ; Lee, Nam Yong</creatorcontrib><description>Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. Results Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P &lt; 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P &lt; 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P &lt; 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). Conclusions Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkl499</identifier><identifier>PMID: 17213265</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Acinetobacter ; Acinetobacter Infections - drug therapy ; Adult ; Aged ; Anti-Bacterial Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; attributable mortality ; Bacteremia - drug therapy ; Bacteremia - mortality ; Bacteria ; Bacterial diseases ; Bacterial sepsis ; Biological and medical sciences ; Cohort Studies ; discordant antimicrobial therapy ; Drug resistance ; Drug Resistance, Bacterial ; Drug therapy ; Female ; Hospitals ; Human bacterial diseases ; Humans ; Imipenem - pharmacology ; Imipenem - therapeutic use ; Infections ; Infectious diseases ; Male ; matched cohort study ; Medical sciences ; Middle Aged ; Mortality ; Multivariate Analysis ; Pharmacology. Drug treatments ; Retrospective Studies</subject><ispartof>Journal of antimicrobial chemotherapy, 2007-03, Vol.59 (3), p.525-530</ispartof><rights>The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2007</rights><rights>2007 INIST-CNRS</rights><rights>The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543</citedby><cites>FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18626358$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17213265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwon, Ki Tae</creatorcontrib><creatorcontrib>Oh, Won Sup</creatorcontrib><creatorcontrib>Song, Jae-Hoon</creatorcontrib><creatorcontrib>Chang, Hyun-Ha</creatorcontrib><creatorcontrib>Jung, Sook-In</creatorcontrib><creatorcontrib>Kim, Shin-Woo</creatorcontrib><creatorcontrib>Ryu, Seong Yeol</creatorcontrib><creatorcontrib>Heo, Sang Taek</creatorcontrib><creatorcontrib>Jung, Dong Sik</creatorcontrib><creatorcontrib>Rhee, Ji-Young</creatorcontrib><creatorcontrib>Shin, Sang Yop</creatorcontrib><creatorcontrib>Ko, Kwan Soo</creatorcontrib><creatorcontrib>Peck, Kyong Ran</creatorcontrib><creatorcontrib>Lee, Nam Yong</creatorcontrib><title>Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. Results Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P &lt; 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P &lt; 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P &lt; 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). Conclusions Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy.</description><subject>Acinetobacter</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>attributable mortality</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - mortality</subject><subject>Bacteria</subject><subject>Bacterial diseases</subject><subject>Bacterial sepsis</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>discordant antimicrobial therapy</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Hospitals</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Imipenem - pharmacology</subject><subject>Imipenem - therapeutic use</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>matched cohort study</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate Analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqF0U1rFTEUBuAgFnutbvwBEgRdCNPmO5NlLdYWLnTTQnETMpkEczszGZMMtf_elLl4wYWuzubhTc55AXiH0SlGip7tjD3rHwam1AuwwUyghiCFX4INoog3knF6DF7nvEMICS7aV-AYS4IpEXwD7q7H2dgCo4dhDLOb3AiTyyEXM1kH4wTHmIoZQnmCYYKzKcFNJcPHUH7AcxsmV2JXA1yC6zBuDOYNOPJmyO7tfp6Au8uvtxdXzfbm2_XF-baxTMrSSEJaXn_SK-Mp4Uz2hmEllcNIKs-l99L3qvOyZ4ga1PasY6KzxFKPpeKMnoBPa-6c4s_F5aLHkK0bBjO5uGQtEUGEc_JfiBUXgklU4Ye_4C4uaapLaIKlaDESz2mfV2RTzDk5r-cURpOeNEb6uRJdK9FrJRW_3ycu3ej6A913UMHHPTDZmsGnevmQD64VRFDeHlxc5n8_2Kyuluh-_ZEmPWghqeT66v67vt9-UYJxpS_pbxS5r18</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>Kwon, Ki Tae</creator><creator>Oh, Won Sup</creator><creator>Song, Jae-Hoon</creator><creator>Chang, Hyun-Ha</creator><creator>Jung, Sook-In</creator><creator>Kim, Shin-Woo</creator><creator>Ryu, Seong Yeol</creator><creator>Heo, Sang Taek</creator><creator>Jung, Dong Sik</creator><creator>Rhee, Ji-Young</creator><creator>Shin, Sang Yop</creator><creator>Ko, Kwan Soo</creator><creator>Peck, Kyong Ran</creator><creator>Lee, Nam Yong</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20070301</creationdate><title>Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia</title><author>Kwon, Ki Tae ; Oh, Won Sup ; Song, Jae-Hoon ; Chang, Hyun-Ha ; Jung, Sook-In ; Kim, Shin-Woo ; Ryu, Seong Yeol ; Heo, Sang Taek ; Jung, Dong Sik ; Rhee, Ji-Young ; Shin, Sang Yop ; Ko, Kwan Soo ; Peck, Kyong Ran ; Lee, Nam Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acinetobacter</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>attributable mortality</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - mortality</topic><topic>Bacteria</topic><topic>Bacterial diseases</topic><topic>Bacterial sepsis</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>discordant antimicrobial therapy</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Hospitals</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Imipenem - pharmacology</topic><topic>Imipenem - therapeutic use</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>matched cohort study</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate Analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwon, Ki Tae</creatorcontrib><creatorcontrib>Oh, Won Sup</creatorcontrib><creatorcontrib>Song, Jae-Hoon</creatorcontrib><creatorcontrib>Chang, Hyun-Ha</creatorcontrib><creatorcontrib>Jung, Sook-In</creatorcontrib><creatorcontrib>Kim, Shin-Woo</creatorcontrib><creatorcontrib>Ryu, Seong Yeol</creatorcontrib><creatorcontrib>Heo, Sang Taek</creatorcontrib><creatorcontrib>Jung, Dong Sik</creatorcontrib><creatorcontrib>Rhee, Ji-Young</creatorcontrib><creatorcontrib>Shin, Sang Yop</creatorcontrib><creatorcontrib>Ko, Kwan Soo</creatorcontrib><creatorcontrib>Peck, Kyong Ran</creatorcontrib><creatorcontrib>Lee, Nam Yong</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwon, Ki Tae</au><au>Oh, Won Sup</au><au>Song, Jae-Hoon</au><au>Chang, Hyun-Ha</au><au>Jung, Sook-In</au><au>Kim, Shin-Woo</au><au>Ryu, Seong Yeol</au><au>Heo, Sang Taek</au><au>Jung, Dong Sik</au><au>Rhee, Ji-Young</au><au>Shin, Sang Yop</au><au>Ko, Kwan Soo</au><au>Peck, Kyong Ran</au><au>Lee, Nam Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>59</volume><issue>3</issue><spage>525</spage><epage>530</epage><pages>525-530</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Objectives To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia. Methods A retrospective, pairwise-matched (1:1), risk-adjusted (age, Pitt bacteraemia score) cohort study was performed at three tertiary care hospitals in Korea from January 2000 to June 2005. Results Forty patients with imipenem non-susceptible Acinetobacter bacteraemia (INAB group) and 40 matched subjects (1:1 ratio) with imipenem-susceptible Acinetobacter bacteraemia (ISAB group) were included. Both groups had similar clinical features related to the severity of illness. The 30 day mortality rate was higher in the INAB group (57.5%) than the ISAB group (27.5%) (P = 0.007). The rate of discordant antimicrobial therapy was higher in the INAB group (65.0%) than the ISAB group (20.0%) (P &lt; 0.001). The 30 day mortality rate was higher in the patients with discordant antimicrobial therapy (67.6%) than concordant antimicrobial therapy (23.9%) (P &lt; 0.001). Multivariate analysis showed that age, the Pitt bacteraemia score, immunosuppressive status, and discordant antimicrobial therapy were independent risk factors for 30 day mortality among patients with Acinetobacter bacteraemia (P &lt; 0.05). When discordant antimicrobial therapy was excluded in the multivariate analysis, the imipenem resistance was associated with 30 day mortality (P = 0.005). Conclusions Imipenem resistance has a significant impact on the mortality rate among patients with Acinetobacter bacteraemia, and this is mainly attributable to the higher rate of discordant antimicrobial therapy.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>17213265</pmid><doi>10.1093/jac/dkl499</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 2007-03, Vol.59 (3), p.525-530
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_70202552
source Oxford Journals Online
subjects Acinetobacter
Acinetobacter Infections - drug therapy
Adult
Aged
Anti-Bacterial Agents - pharmacology
Antibiotics. Antiinfectious agents. Antiparasitic agents
attributable mortality
Bacteremia - drug therapy
Bacteremia - mortality
Bacteria
Bacterial diseases
Bacterial sepsis
Biological and medical sciences
Cohort Studies
discordant antimicrobial therapy
Drug resistance
Drug Resistance, Bacterial
Drug therapy
Female
Hospitals
Human bacterial diseases
Humans
Imipenem - pharmacology
Imipenem - therapeutic use
Infections
Infectious diseases
Male
matched cohort study
Medical sciences
Middle Aged
Mortality
Multivariate Analysis
Pharmacology. Drug treatments
Retrospective Studies
title Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A49%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20imipenem%20resistance%20on%20mortality%20in%20patients%20with%20Acinetobacter%20bacteraemia&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Kwon,%20Ki%20Tae&rft.date=2007-03-01&rft.volume=59&rft.issue=3&rft.spage=525&rft.epage=530&rft.pages=525-530&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dkl499&rft_dat=%3Cproquest_cross%3E1317815101%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c477t-72285213d9af32547da41979e1079f57ff7fd9bf7d403a08d4b46bc2c3f179543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=217681062&rft_id=info:pmid/17213265&rft_oup_id=10.1093/jac/dkl499&rfr_iscdi=true